Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03657433 · ClinicalTrials.gov registry record · Phase 3
Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy
A Phase 3 study of Iron Deficiency Anemia of Pregnancy, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT03657433: Completed Phase 3 study of Iron Deficiency Anemia of Pregnancy, sponsored by University of Arizona.
NCT03657433 is a Phase 3 study of Iron Deficiency Anemia of Pregnancy that has completed, run by University of Arizona. The registered enrollment target is 124 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03657433, a Phase 3 study of Iron Deficiency Anemia of Pregnancy, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized controlled trial includes pregnant women with anemia. They are randomized to IV iron infusions or to oral iron supplementation. Pregnancy outcomes are assessed.
Primary Outcome
We will assess the increase in maternal hemoglobin during the study timeframe
Conditions Studied
Interventions
- DRUG Ferumoxytol
- DIETARY_SUPPLEMENT Ferrous sulfate 325mg
Study Locations (1)
Arizona
- University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2018-12-17 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 3 |
What the finished NCT03657433 record still lists
NCT03657433 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Iron Deficiency Anemia of Pregnancy appearing as the primary indexed condition, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT03657433 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03657433 about?
NCT03657433 is a clinical study titled "Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy". This randomized controlled trial includes pregnant women with anemia. They are randomized to IV iron infusions or to oral iron supplementation. Pregnancy outcomes are assessed.
What is the current status of trial NCT03657433?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2018-12-17. Estimated completion is 2022-04-01.
What conditions does trial NCT03657433 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia of Pregnancy.
What interventions are being tested in trial NCT03657433?
The interventions under investigation include: Ferumoxytol (DRUG), Ferrous sulfate 325mg (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03657433?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03657433 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia of Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03657433's enrollment target sits among peer trials
124 1610th of 2000 higher than 386 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI